Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 12/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460246 | 0.92 | GRIA1 (0.34) | PLATGRIA2POLB | |
| Tert-Butyl Formate SCHEMBL27862135 | 0.91 | PLAT (0.38) | PLATTLR9TLR8TLR7GRIA2 | |
| SCHEMBL1463510 | 0.90 | ATR (0.36) | PLATGRIA2 | |
| SCHEMBL1460353 | 0.86 | TGFBR1 (0.40) | TLR9TLR8TLR7PRMT5 | |
| SCHEMBL1462834 | 0.86 | TLR9 (0.36) | TLR9TLR8TLR7 | |
| SCHEMBL27862098 | 0.85 | TLR9 (0.41) | TLR9TLR8TLR7 | |
| SCHEMBL1462534 | 0.85 | ATR (0.37) | PLATTLR9TLR8TLR7GRIA2 | |
| SCHEMBL27862133 | 0.83 | IDH1 (0.34) | TLR9TLR8TLR7 | |
| SCHEMBL1460273 | 0.82 | HTT (0.43) | PRMT5MEN1KMT2A | |
| SCHEMBL12745974 | 0.78 | ALOX5 (0.40) | PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | PLAT 4883/4885TLR9 4467/4885TLR8 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.